Comparison of the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation

Randomized Controlled Trial Comparing the Long GnRH Agonist Protocol and the Flexible GnRH Antagonist Protocol of Ovarian Stimulation in Normal Responders

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00417183

Enrollment

300

Registered

2006-12-29

Start date

2005-09-30

Completion date

2007-06-30

Last updated

2006-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

GnRH antagonist, GnRH agonist, Long protocol, Flexible

Brief summary

The purpose of this study is to compare the efficacy of two controlled ovarian stimulation protocols, the GnRH agonist protocol, widely known as the long protocol, and the flexible GnRH antagonist protocol, in terms of pregnancy rates and embryological data, in infertile patients receiving IVF treatment.

Detailed description

The formulation of controlled ovarian stimulation protocols is one of the primary reasons for the successful development of IVF. The long GnRH agonist protocol, also known as the gold standard, has been widely used with considerable success. More recently, on the other hand, GnRH antagonist provide a new promising approach for endogenous gonadotrophin suppression by blocking the GnRH receptor. There is conflicting data in the literature regarding the relative merits of the two ovarian stimulation protocols. COMPARISON: Pregnancy rates and embryological data will by assessed in IVF patients treated with either the long GnRH agonist (Arvekap) or the flexible GnRH antagonist (Ganirelix) protocol.

Interventions

DRUGArvekap 0.1 mg (Triptorelin, Ipsen, France)

DRUGGanirelix 0.25 (Orgalutran, Organon, The Netherlands)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

21 Years to 39 Years

Healthy volunteers

Yes

Inclusion criteria

* Age 18-39 years * Body mass index 18-29 kg/m2 * Menstrual cycle from 24-35 days * Normal basal FSH (\<10 IU/ml) * Normal basal LH (\<10 IU/ml) * Normal basal estradiol (\<80 pg/ml)

Exclusion criteria

* Poor responder patients * Polycystic ovaries

Design outcomes

Primary

Measure	Time frame
Ongoing pregnancy per embryo transfer	—

Secondary

Measure	Time frame
Biochemical pregnancy per embryo transfer	—
Clinical pregnancy per embryo transfer	—
Embryological data	—

Countries

Greece

Contacts

Primary ContactTryfon Lainas, PhD

ivf@eugonia.com.gr00302107236333

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026